Welcome to our dedicated page for Know Labs news (Ticker: KNWND), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
News related to Know Labs, Inc. (symbol KNWND in the period referenced) centers on its Radio Frequency Dielectric Spectroscopy (RFDS) sensor platform, intellectual property developments, and trading status on public markets. The company issues updates describing how its RFDS technology is intended to capture unique molecular signatures and be integrated into wearable, mobile, or bench-top form factors, with early attention on non-invasive glucose monitoring.
Investors and observers following Know Labs news can expect announcements about its intellectual property portfolio, including counts of issued, pending, and in-process patents and codified trade secrets. The company has highlighted third-party analyses of its patents in certain medical diagnostics and industrial process control categories, as well as the role of the Tangibly platform in organizing its trade secrets.
Another recurring news theme involves Know Labs Technology Licensing (KTL), the company’s licensing division. Releases describe KTL’s role in enabling corporations, universities, and research institutions to access the RFDS platform under a structured licensing framework, supported by the proprietary e-RFDS© digital watermark.
Know Labs news also covers trading and listing developments, such as approval to quote its common shares on the OTCQB Venture Market and regulatory decisions regarding trading suspension and continued listing standards on the NYSE American. Readers can use this news feed to review company statements on its technology roadmap, licensing activities, intellectual property strategy, and market listing status over time.
Know Labs announced that NYSE Regulation has withdrawn its delisting determination and will lift the trading suspension of the company's common stock on the NYSE American. Trading is expected to resume on March 5, 2025, under the symbol 'KNW'.
While the immediate trading suspension is lifted, Know Labs remains under a compliance plan accepted by NYSE American on December 10, 2024. The company has until March 27, 2026, to regain compliance with continued listing standards under Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide. Failure to meet compliance standards or show consistent progress could result in renewed delisting proceedings.
Know Labs (OTC: KNWN) has received approval to begin trading on the OTCQB Venture Market effective February 26, 2025. The company, specializing in Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology, will trade under the symbol 'KNWN'. Following a reverse stock split announced by FINRA on February 18, 2025, the symbol temporarily carries a 'D' designation for 20 days from February 19, 2025.
The OTCQB market, recognized by the SEC as an established public market, requires companies to maintain current financial reporting, pass minimum bid price requirements, and undergo annual verification. This upgrade is expected to provide enhanced transparency, improved market depth disclosure, and potentially better liquidity for shareholders.
Know Labs (OTC: KNWND), a leader in Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology, has announced updates to its intellectual property portfolio. The company currently holds 325 patents (issued, pending, and in process) and has revealed a library of 1,022 trade secrets codified through the Tangibly platform.
According to an independent analysis by PatSnap, Know Labs' patent portfolio ranks first globally in specific categories of medical diagnostics and industrial process control. The company's IP strategy involves both patents and trade secrets, with the latter being disclosed publicly for the first time as part of their Know Labs Technology Licensing (KTL) initiative.
The slight reduction from previously reported 332 patent assets is attributed to combining provisional patents into utility patents and strategic abandonment of less critical pending patents. The company emphasizes that both patents and trade secrets will continue to grow as innovation progresses.